Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis

January 1999
Thorax;Jan1999, p91
Academic Journal
No abstract available.


Related Articles

  • Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis. Adis International Limited // Drugs & Therapy Perspectives;Sep2004, Vol. 20 Issue 9, p1 

    Focuses on the effects of inhaled tobramycin on lung function and bacterial density associated with Pseudomonas aeruginosa infections in cystic fibrosis patients. Clinical benefits and potential limitations of tobramycin solution for inhalation (TSI) in the management of Pseudomonas aeruginosa...

  • Pulmonary.  // Africa Health;Jul2011, Vol. 33 Issue 5, p59 

    The article reports on a 5-year follow-up for acute respiratory distress syndrome (ARDS), the large part played by nebulised recombinant human DNase in adults with cystic fibrosis, and the use of inhaled long-acting bronchodilators for patients with severe chronic obstructive pulmonary disease.

  • Effect of Recombinant Human DNase on a1-Proteinase Inhibitor Function: An Experimental Approach to the Combined Clinical Use of rhDNase and a1-PI in CF Patients. Hansen, G.; Hoffjan, S.; Mosler, K.; Schuster, A. // Lung;2001, Vol. 179 Issue 3, p185 

    Chronic inflammation in cystic fibrosis (CF) airways leads to high concentrations of deoxyribonucleic acid (DNA) and neutrophil elastase (NE). Both play a major role in CF lung pathophysiology and are aims of new therapeutic approaches: rhDNase degrades highly viscosic DNA and a1-proteinase...

  • Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Sanders, N. N.; Franckx, H.; de Boeck, K.; Hausfraete, J.; de Smedt, S. C.; Demeester, J. // Thorax;Nov2006, Vol. 61 Issue 11, p962 

    Background: In the management of cystic fibrosis (CF), rhDNase-I inhalation is widely used to facilitate the removal of the highly viscous and elastic mucus (often called sputum) from the lungs. However, an important group of CF patients does not benefit from rhDNase-l treatment. A study was...

  • CITATIONS AND CLINICIANS' NOTES: CYSTIC FIBROSIS.  // Current Medical Literature: Respiratory Medicine;2005, Vol. 19 Issue 2, p45 

    Presents citations and clinicians' notes about cystic fibrosis. Tobramycin treatment for pulmonary exacerbations of cystic fibrosis; Peak oxygen uptake and mortality in children with cystic fibrosis; Bronchial constriction and inhaled colistin in cystic fibrosis; Use of trampoline as a...

  • Cystic Fibrosis.  // Current Medical Literature: Respiratory Medicine;2007, Vol. 21 Issue 2, p50 

    The article presents abstracts of research on cystic fibrosis. They include "Spirometry in Early Childhood in Cystic Fibrosis Patients," "Alpha1-Antitrypsin Inhalation Reduces Airway Inflammation in Cystic Fibrosis Patients" and "Human Metapneumovirus and Respiratory Syncytial Virus Infections...

  • Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. Vandivier, R. William; Fadok, Valerie A.; Hoffmann, Peter R.; Bratton, Donna L.; Penvari, Churee; Brown, Kevin K.; Brain, Joseph D.; Accurso, Frank J.; Henson, Peter M. // Journal of Clinical Investigation;3/1/2002, Vol. 109 Issue 5, p661 

    Cystic fibrosis is characterized by an early and sustained influx of inflammatory cells into the airways and by release of proteases. Resolution of inflammation is normally associated with the orderly removal of dying apoptotic inflammatory cells through cell recognition receptors, such as the...

  • Cystic Fibrosis.  // Current Medical Literature: Respiratory Medicine;2006, Vol. 20 Issue 2, p40 

    The article presents abstracts of research related to cystic fibrosis. They include "A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis," "Exhaled nitric oxide is not reduced in infants with cystic fibrosis" and "Restoring airway surface liquid in cystic...

  • CAYSTON.  // MPR - Pediatricians' Edition;Spring/Summer2010, Vol. 21 Issue 1, pA.5 

    The article features Cayston, an inhalation solution developed for the improvement of respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

  • Meconium ileus equivalent in older patients with cystic fibrosis. Hanly, J.G.; Fitzgerald, M.X. // British Medical Journal (Clinical Research Edition);4/30/1983, Vol. 286 Issue 6375, p1411 

    Examines on meconium ileus manifestations of cystic fibrosis in older patients. Survival of patients with cystic fibrosis; Occurrence of symptoms of gastrointestinal in cases of cystic fibrosis; Response of patient in the medical treatment.


Read the Article


Sign out of this library

Other Topics